- Start
- Mar 31, 202750% CONFIDENCEfrom the source
Lilly Submits Retatrutide to the FDA for Approval
- Lilly said on 23 July 2026 that it is completing the Chemistry, Manufacturing, and Controls (CMC) data package required for a Biologics License Application and "plans to subsequently submit retatrutide in Q1 2027 for U.S. approval"[1]
- Its second-quarter results on 5 August repeated the plan: the clinical data package is complete to support global registrations for obesity, obstructive sleep apnea and knee osteoarthritis pain, "with plans to submit a Biologics License Application to the U.S. FDA in the first quarter of 2027"[2]
- The filing had earlier been expected later in 2026[4]; Lilly told CNBC it needed more time to gather manufacturing and quality-control data for the agency[3]
- The package rests on five positive Phase 3 studies[1]; in the last two, TRIUMPH-2 patients with type 2 diabetes lost 12.7%, 19.1% and 20.8% of their weight on 4, 9 and 12 mg (up to 49.6 lbs) with A1C down by up to 1.6% at 80 weeks, and TRIUMPH-3 patients with severe obesity and heart disease lost up to 22.6% (55.8 lbs)[1]
- Heart outcomes were less clear-cut: TRIUMPH-3 saw 44 MACE-5 events on retatrutide against 52 on placebo (hazard ratio 0.82), but 27 MACE-3 events against 23 (hazard ratio 1.12)[1][3]
- "We now have the clinical data package to support global submissions for retatrutide," said Kenneth Custer, president of Lilly Cardiometabolic Health[1]
References 477% CONFIDENCE
The first entry is always the pin's source. Overall confidence is a weighted average of how firmly each reference supports the start and end times used above; a reference counts half as much for every 180 days older than the newest.
- [1]50%prnewswire.com/news-releases/lillys-triple-agonist-retatrutide-successful-in-two-additional-phase-3-obesity-trials-delivering-significant-improvements-in-weight-and-a1c-302832674.htmlprnewswire.com· Posted Sep 23, 2026· Starts Mar 31, 2027 ✓· 29% of score
Lilly "plans to subsequently submit retatrutide in Q1 2027 for U.S. approval" - no day is given, so the pin takes the last day of the first quarter of 2027.
- [2]92%Lilly reports second-quarter 2026 financial results (Form 8-K Exhibit 99.1)sec.gov· Published Aug 5, 2026· 24% of score
Lilly's Q2 2026 earnings release filed with the SEC on 5 August 2026: the retatrutide clinical data package is complete to support global registrations for obesity, obstructive sleep apnea and knee osteoarthritis pain, "with plans to submit a Biologics License Application to the U.S. FDA in the first quarter of 2027".
- [3]88%Lilly, with new data, to seek FDA approval of obesity drug retatrutidebiopharmadive.com· Published Jul 23, 2026· 23% of score
BioPharma Dive, 23 July 2026: Lilly earlier included retatrutide among medicines that might be submitted by the end of 2026 but now says it is set for an FDA application in the first quarter of next year; Lilly told CNBC it needed more time to gather manufacturing and quality-control data; TRIUMPH-3 MACE-3 27 vs 23.
- [4]85%Lilly preps FDA run for 'triple-G' weight loss drug with Phase 3 databiospace.com· Published Jul 23, 2026· 23% of score
BioSpace (Tristan Manalac), 23 July 2026: with weight loss topping 20% at 80 weeks in TRIUMPH-2 and TRIUMPH-3, Lilly plans to file for retatrutide's approval in the first quarter of 2027; "Previously a filing was expected later this year."
Suggest a correction
Something missing or wrong? Say it in your own words: a link that backs this pin up, a different start or end date and why, or a fact it lacks or gets wrong. The AI checks it against this pin's sources, searches for better ones, and adds any page that backs you up. The pin's own sources still count most.
